aTyr Pharma Announces 2024 Annual Meeting of Stockholders on May 22, 2024
Ticker: ATYR · Form: DEF 14A · Filed: Apr 5, 2024 · CIK: 1339970
| Field | Detail |
|---|---|
| Company | Atyr Pharma Inc (ATYR) |
| Form Type | DEF 14A |
| Filed Date | Apr 5, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 20 min |
| Key Dollar Amounts | $15,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual meeting, proxy statement, director election, executive compensation, stock plan
TL;DR
<b>aTyr Pharma will hold its 2024 Annual Meeting of Stockholders on May 22, 2024, to elect directors, ratify auditors, and vote on executive compensation and stock plan amendments.</b>
AI Summary
aTYR PHARMA INC (ATYR) filed a Proxy Statement (DEF 14A) with the SEC on April 5, 2024. The 2024 Annual Meeting of Stockholders for aTyr Pharma, Inc. will be held on May 22, 2024, at 9:00 a.m. Pacific Time. The meeting agenda includes the election of two Class III directors, ratification of Ernst & Young LLP as independent auditors, and advisory approval of executive compensation. Stockholders will also vote on an amendment to the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan. The company is seeking authorization to adjourn the meeting if necessary to solicit additional proxies for Proposal 4. The proxy statement will be mailed to stockholders on or about April 5, 2024.
Why It Matters
For investors and stakeholders tracking aTYR PHARMA INC, this filing contains several important signals. This meeting is a critical juncture for shareholders to influence the company's future leadership and compensation practices. The proposed amendment to the stock option plan could impact future equity-based compensation and shareholder dilution.
Risk Assessment
Risk Level: low — aTYR PHARMA INC shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would alter the company's risk profile.
Analyst Insight
Stockholders should review the proxy materials carefully to make informed decisions on director elections, executive compensation, and the proposed stock plan amendment.
Key Numbers
- 2 — Class III directors (To be elected at the Annual Meeting)
- 2027 — Director term end (Term for newly elected directors)
- 2024 — Fiscal year end (Fiscal year for which Ernst & Young LLP is proposed to be ratified)
Key Players & Entities
- aTyr Pharma, Inc. (company) — Registrant and filer of the proxy statement
- Ernst & Young LLP (company) — Proposed independent registered public accounting firm
- May 22, 2024 (date) — Date of the Annual Meeting of Stockholders
- April 5, 2024 (date) — Expected mailing date of the Notice of Internet Availability of Proxy Materials
FAQ
When did aTYR PHARMA INC file this DEF 14A?
aTYR PHARMA INC filed this Proxy Statement (DEF 14A) with the SEC on April 5, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by aTYR PHARMA INC (ATYR).
Where can I read the original DEF 14A filing from aTYR PHARMA INC?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by aTYR PHARMA INC.
What are the key takeaways from aTYR PHARMA INC's DEF 14A?
aTYR PHARMA INC filed this DEF 14A on April 5, 2024. Key takeaways: The 2024 Annual Meeting of Stockholders for aTyr Pharma, Inc. will be held on May 22, 2024, at 9:00 a.m. Pacific Time.. The meeting agenda includes the election of two Class III directors, ratification of Ernst & Young LLP as independent auditors, and advisory approval of executive compensation.. Stockholders will also vote on an amendment to the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan..
Is aTYR PHARMA INC a risky investment based on this filing?
Based on this DEF 14A, aTYR PHARMA INC presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would alter the company's risk profile.
What should investors do after reading aTYR PHARMA INC's DEF 14A?
Stockholders should review the proxy materials carefully to make informed decisions on director elections, executive compensation, and the proposed stock plan amendment. The overall sentiment from this filing is neutral.
How does aTYR PHARMA INC compare to its industry peers?
aTyr Pharma operates in the biotechnology sector, focusing on developing novel protein therapeutics.
Are there regulatory concerns for aTYR PHARMA INC?
The filing is a proxy statement (DEF 14A) filed under the Securities Exchange Act of 1934, requiring adherence to specific disclosure and solicitation rules.
Risk Factors
- Compliance with SEC Regulations [low — regulatory]: The company must comply with all SEC regulations regarding proxy solicitations and annual meetings, including timely filing and accurate disclosure.
- Effectiveness of Board of Directors [medium — operational]: The election of directors is crucial for the company's strategic direction and oversight.
- Stock Option and Incentive Plan [medium — financial]: The proposed amendment to the stock option plan could affect future equity compensation and potential dilution.
Industry Context
aTyr Pharma operates in the biotechnology sector, focusing on developing novel protein therapeutics.
Regulatory Implications
The filing is a proxy statement (DEF 14A) filed under the Securities Exchange Act of 1934, requiring adherence to specific disclosure and solicitation rules.
What Investors Should Do
- Review the qualifications and backgrounds of the nominated directors.
- Evaluate the proposed amendment to the 2015 Stock Option and Incentive Plan.
- Understand the advisory vote on executive compensation and its implications.
Key Dates
- 2024-05-22: Annual Meeting of Stockholders — Election of directors, ratification of auditors, advisory vote on executive compensation, and vote on stock plan amendment.
- 2024-04-05: Mailing of Proxy Materials — Stockholders will receive notice of internet availability of proxy materials.
Year-Over-Year Comparison
This is a routine DEF 14A filing for the annual meeting and does not represent a change from previous filings in terms of core financial or operational data.
Filing Stats: 4,882 words · 20 min read · ~16 pages · Grade level 13.1 · Accepted 2024-04-05 16:00:29
Key Financial Figures
- $15,000 — ry fee, which is not expected to exceed $15,000. We will also reimburse brokerage firms
Filing Documents
- 2024_def_proxy_stmt_no_x.htm (DEF 14A) — 1245KB
- img153403655_0.jpg (GRAPHIC) — 13KB
- img153403655_1.jpg (GRAPHIC) — 117KB
- img153403655_2.jpg (GRAPHIC) — 122KB
- img153403655_3.jpg (GRAPHIC) — 13KB
- img153403655_4.jpg (GRAPHIC) — 1275KB
- img153403655_5.jpg (GRAPHIC) — 444KB
- 0000950170-24-042236.txt ( ) — 3967KB
FORWARD-LOOKING STATEMENTS
FORWARD-LOOKING STATEMENTS 6 PROPOSAL 1 - ELECTION OF DIRECTORS 7 PROPOSAL 2 - RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 15 PROPOSAL 3 – ADVISORY VOTE ON NAMED EXECUTIVE OFFICER COMPENSATION 16 PROPOSAL 4 - APPROVAL OF AN AMENDMENT TO THE 2015 STOCK OPTION AND INCENTIVE PLAN, AS AMENDED 17 PROPOSAL 5 - AUTHORIZATION TO ADJOURN THE ANNUAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES 24 EXECUTIVE OFFICERS 25
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 25 PAY VERSUS PERFORMANCE 39 DIRECTOR COMPENSATION 42 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 44
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 45 AUDIT COMMITTEE REPORT 47 STOCKHOLDER PROPOSALS FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS 48 HOUSEHOLDING OF PROXY MATERIALS 48 OTHER MATTERS 49 i ATYR PHARMA, INC. PROXY ST ATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held On May 22, 2024 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why did I receive a notice regarding the availability of proxy materials on the internet? Pursuant to rules adopted by the Securities and Exchange Commission (the “SEC”), we have elected to provide access to our proxy materials over the internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the “Notice”) because the Board of Directors of the Company is soliciting your proxy to vote at the 2024 Annual Meeting of Stockholders (the “Annual Meeting”), including at any adjournments or postponements of the meeting. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the proxy materials over the internet or to request a printed copy may be found in the Notice. We intend to mail the Notice on or about April 5, 2024 to all stockholders of record entitled to vote at the Annual Meeting. Will I receive any other proxy materials by mail? W e may send you a proxy card, along with a second Notice, after April 15, 2024. How do I attend the Annual Meeting? The meeting will be held on Wednesday, May 22, 2024 at 9:00 AM Pacific Time at the Company’s corporate headquarters located at 10240 Sorrento Valley Road, San Diego, California 92121 . Information on how to vote in person at the Annual Meeting is discussed below. Who can vote at the Annual Meeting? Only stockholders of record at the close of busi
FORWARD-LOOKING STATEMENTS
FORWARD-LOOKING STATEMENTS This proxy statement contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, relating to future events, including, without limitation, our beliefs regarding whether NYSE will determine the proposals in this proxy statement to be “routine” or “non-routine” and the existence of “broker non-votes” as a result of such determinations. Such statements are only predictions and involve risks and uncert